Neal D. Shore, MD, presented “Phase III HERO Trial: Once-Daily, Oral Relugolix Results in 96.7% Testosterone Suppression in Men with Advanced Prostate Cancer” for the Grand Rounds in Urology audience in November 2019.
How to cite: Shore, Neal D. “Phase III HERO Trial: Once-Daily, Oral Relugolix Results in 96.7% Testosterone Suppression in Men with Advanced Prostate Cancer” November, 2019. Accessed Jul 2024. https://grandroundsinurology.com/phase-iii-hero-trial/
Phase III HERO Trial: Once-Daily, Oral Relugolix Results in 96.7% Testosterone Suppression in Men with Advanced Prostate Cancer – Summary:
Neal D. Shore, MD, a HERO Program Steering Committee Member, discusses the results of his group’s global, prospective, randomized, phase III trial. This trial evaluated once-daily, oral relugolix, a gonadotropin-releasing hormone (GnRH) antagonist, for the treatment of advanced prostate cancer against a control arm of patients receiving 3-month leuprolide injections. The primary endpoint of sustained testosterone suppression for 48 weeks was met, as well as 6 key secondary endpoints, and the reported major adverse cardiovascular events favored relugolix over the control arm.
ABOUT THE AUTHOR
Neal D. Shore, MD, FACS, graduated from Duke University and Duke University Medical School. He completed his general surgery/urology residency at New York Hospital-Cornell Medical Center/Memorial Sloan Kettering Cancer Center. He serves as the Medical Director for the Carolina Urologic Research Center and is the Chief Medical Officer, Strategic Growth and Pharmacy, GenesisCare, US.
Dr. Shore has conducted more than 400 clinical trials, focusing mainly on genitourinary oncology, and has authored or coauthored more than 350 peer-reviewed publications and numerous book chapters. He serves on the Society for Immunotherapy of Cancer (SITC) Guidelines Committee for Bladder Cancer, as well as the boards of the Bladder Cancer Advocacy Network, Maple Tree Alliance, and the Duke Global Health Institute. He is the Chair of both the Prostate Cancer Academy and the Bladder/Kidney Cancer Academy for the Large Urology Group Practice Association (LUGPA) Specialty Network. He also co-chairs the annual AUA International Prostate Forum. He has served/serves on the editorial boards of Reviews in Urology, Urology Times, Chemotherapy Advisor, OncLive, PLOS ONE, Urology Practice, JUOP and World Journal of Urology, and he also serves as an editor of Everyday Urology-Oncology. He is a Fellow of the American College of Surgeons.
